Autologous hematopoietic transplantation following COVID‐19 infection

Autologous hematopoietic cell transplantation following induction therapy is standard of care for most patients with newly diagnosed multiple myeloma (N Engl J Med 2017, 376; 1311). Though active COVID‐19 infection is typically a contraindication to aggressive therapy, little is known about the safe...

Descripción completa

Detalles Bibliográficos
Autores principales: Brzycki, Marthilde, Richard, Robert, Burwick, Nicholas, Graf, Solomon, O'Brien, Craig, Wu, Daniel, Chauncey, Thomas R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981617/
https://www.ncbi.nlm.nih.gov/pubmed/33768803
http://dx.doi.org/10.1002/ccr3.3712
Descripción
Sumario:Autologous hematopoietic cell transplantation following induction therapy is standard of care for most patients with newly diagnosed multiple myeloma (N Engl J Med 2017, 376; 1311). Though active COVID‐19 infection is typically a contraindication to aggressive therapy, little is known about the safety of autologous transplantation after resolution of acute symptoms and undetectable pathogen by nasopharyngeal PCR.

Ejemplares similares